Abstract:Background: It has been more than a year since the whole world is struggling with COVID-19 pandemic and may experience resurgences in the near future. Along with severe pneumonia, this disease is notorious for extensive thromboembolic manifestations. That is why experts advocated aggressive anticoagulation as a part of the therapy since the beginning. However, from May 2020 onwards, cases of heparin-induced thrombocytopenia (HIT) are being reported. HIT in itself is an autoimmune entity leading to life-threatening thrombosis in the setting of thrombocytopenia. Continuation of heparin can have disastrous consequences in case of unrecognized HIT. Hence, timely recognition of HIT is of utmost value to modify the anticoagulation strategy and salvaging lives. We performed a systemic review trying to find all reported cases of HIT in COVID-19. Methods: It involved extensive search of the databases including PubMed, Google Scholar, Scopus, and Embase in an attempt to find all reported literature in the last 1 year (November 1, 2019-December 25, 2020) using keywords in various combinations. Literature search resulted in a total of 27 articles and 12 articles were finally selected based on the study design and their relevance pertaining to the intervention done and the outcome of interest. Results: A total of 35 patients were included (mean age 56.7 ± 12.8 years, male-to-female ratio = 2:1). The most frequent comorbidity was hypertension. Fifty-seven percent of cases were with low-molecular weight heparin and the rest with unfractionated heparin. Confirmatory functional assay was done in 85.7% of cases (67% by serotonin-release assay [SRA] and 33% by heparin-induced platelet aggregation [HIPA]). All cases tested with HIPA were positive, while with SRA, only 30% were positive. The most common alternate anticoagulation used was argatroban infusion. The new arterial thrombotic event was seen in only 5.7% of cases as repeat myocardial infarction, stroke, and splenic infarction, while clinically significant bleeding was seen in 17.1% of cases. Fifty percent of bleeding episodes were seen where conventional doses of argatroban were used, while no mortality was seen with low-dose argatroban infusion. However, only 45.7% of patients were discharged, 31.4% of patients died, while the outcome was pending for 23% of patients. Conclusion: Severe endotheliitis and immune dysregulation giving rise to HIT antibodies and antiphospholipid antibodies have been demonstrated in COVID-19 and modifying our therapy becomes indispensable when it is pathogenic with potentially fatal consequences. In the light of interim results of REMAP-CAP study in severe COVID-19 cases where heparin does not improve the outcome, the present anticoagulation strategy needs re-evaluation. Unrecognized HIT can be catastrophic and close clinical monitoring is required for patients on heparin therapy.

Therapeutic anti-coagulation in COVID-19 and the potential enhanced risk of retroperitoneal hematoma

Hemorrhage and Venous Thromboembolism in Critically Ill Patients with COVID-19

Life-Threatening Retroperitoneal Hematoma in a Patient with COVID-19

Spontaneous retroperitoneal hematoma: a rare bleeding occurrence in COVID-19

Parenteral Anticoagulation and Retroperitoneal Hemorrhage in COVID-19: Case Report of Five Patients

The Risk of Thrombosis after Acute-Covid-19 Infection

Fatal retroperitoneal hematoma associated with Covid-19 prophylactic anticoagulation protocol

Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic

Role of Therapeutic Anticoagulation in COVID-19: The Current Situation

A review of pathophysiological mechanism, diagnosis, and treatment of thrombosis risk associated with COVID-19 infection

Anticoagulation for COVID-19 Patients: A Bird's-Eye View

The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications

Racial Disparities in the Risk for Thromboembolic Events in COVID-19 Patients during the Height of the SARS-CoV-2 Pandemic and Impact on Outcomes

COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic

Heparin-Induced Thrombocytopenia in COVID-19: A Systematic Review

Risk Factors for Systemic and Venous Thromboembolism, Mortality and Bleeding Risks in 1125 Patients with COVID-19: Relationship with Anticoagulation Status

COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year

Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients

Impacts of COVID-19 on hemostasis: coagulation abnormalities and management perspectives

Therapeutic vs. prophylactic anticoagulation in COVID-19 patients: a systematic review and meta-analysis of real-world studies

Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta‐analysis